Dental enamel development occurs in stages as observed by the changing morphology of the ameloblasts that are responsible for enamel formation. During the secretory stage of development, proteins including MMP20 are secreted into the enamel matrix. MMP20 is required for proper enamel formation as mutation of the Mmp20 gene causes autosomal recessive amelogenesis imperfecta. Here, we examined in detail the morphology of the Mmp20-null ameloblast cell layer. Intriguingly, we found that the Mmp20-null mouse secretory stage ameloblasts retract their Tomes’ processes as if preparing to enter the maturation stage but later reextend their Tomes’ processes as if resuming the secretory stage. We also demonstrated that MMP20 cleaves epithelial cadherin, i.e. E-cadherin. Cadherins are transmembrane proteins with extracellular domains that provide adhesive contacts between neighboring cells. Their intracellular domains bind to the cell cytoskeleton through catenins, including β-catenin. When specific MMPs cleave the cadherin extracellular domain, β-catenin is released and may locate to the cell nucleus as a transcription factor. Therefore, MMP20 may influence ameloblast developmental progression through hydrolysis of cadherin extracellular domains with associated release of transcription factor(s).

Keywords:
Matrix metalloproteinases, Adhesion, Cell junctions
1.
Bartlett, J.D., E. Beniash, D.H. Lee, C.E. Smith (2004) Decreased mineral content in MMP-20 null mouse enamel is prominent during the maturation stage. J Dent Res 83: 909–913.
2.
Bartlett, J.D., J.M. Dobeck, C.E. Tye, M. Perez-Moreno, N. Stokes, A.B. Reynolds, E. Fuchs, Z. Skobe (2010) Targeted p120-catenin ablation disrupts dental enamel development. PLoS One 5: e12703.
3.
Bartlett, J.D., Z. Skobe, D.H. Lee, J.T. Wright, Y. Li, A.B. Kulkarni, C.W. Gibson (2006) A developmental comparison of matrix metalloproteinase-20 and amelogenin null mouse enamel. Eur J Oral Sci 114(suppl 1): 18–23.
4.
Caterina, J.J., Z. Skobe, J. Shi, Y. Ding, J.P. Simmer, H. Birkedal-Hansen, J.D. Bartlett (2002) Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem 277: 49598–49604.
5.
Cowden Dahl, K.D., J. Symowicz, Y. Ning, E. Gutierrez, D.A. Fishman, B.P. Adley, M.S. Stack, L.G. Hudson (2008) Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 68: 4606–4613.
6.
Davis, M.A., R.C. Ireton, A.B. Reynolds (2003) A core function for p120-catenin in cadherin turnover. J Cell Biol 163: 525–534.
7.
Fausser, J.L., O. Schlepp, D. Aberdam, G. Meneguzzi, J.V. Ruch, H. Lesot (1998) Localization of antigens associated with adherens junctions, desmosomes, and hemidesmosomes during murine molar morphogenesis. Differentiation 63: 1–11.
8.
Ferber, A., C. Yaen, E. Sarmiento, J. Martinez (2002) An octapeptide in the juxtamembrane domain of VE-cadherin is important for p120ctn binding and cell proliferation. Exp Cell Res 274: 35–44.
9.
Hartsock, A., W.J. Nelson (2008) Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 1778: 660–669.
10.
Heymann, R., I. About, U. Lendahl, J.C. Franquin, B. Obrink, T.A. Mitsiadis (2002) E- and N-cadherin distribution in developing and functional human teeth under normal and pathological conditions. Am J Pathol 160: 2123–2133.
11.
Kim, J.W., J.P. Simmer, T.C. Hart, P.S. Hart, M.D. Ramaswami, J.D. Bartlett, J.C. Hu (2005) MMP-20 mutation in autosomal recessive pigmented hypomaturation amelogenesis imperfecta. J Med Genet 42: 271–275.
12.
Lee, S.K., F. Seymen, H.Y. Kang, K.E. Lee, K. Gencay, B. Tuna, J.W. Kim (2010) MMP20 hemopexin domain mutation in amelogenesis imperfecta. J Dent Res 89: 46–50.
13.
Lochter, A., S. Galosy, J. Muschler, N. Freedman, Z. Werb, M.J. Bissell (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861–1872.
14.
Lynch, C.C., T. Vargo-Gogola, L.M. Matrisian, B. Fingleton (2010) Cleavage of E-cadherin by matrix metalloproteinase-7 promotes cellular proliferation in nontransformed cell lines via activation of RhoA. J Oncol 2010: 530745.
15.
Maeda, M., E. Johnson, S.H. Mandal, K.R. Lawson, S.A. Keim, R.A. Svoboda, S. Caplan, J.K. Wahl 3rd, M.J. Wheelock, K.R. Johnson (2006) Expression of inappropriate cadherins by epithelial tumor cells promotes endocytosis and degradation of E-cadherin via competition for p120(ctn). Oncogene 25: 4595–4604.
16.
McGuire, J.K., Q. Li, W.C. Parks (2003) Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162: 1831–1843.
17.
Munshi, H.G., M.S. Stack (2006) Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev 25: 45–56.
18.
Nagano, T., A. Kakegawa, Y. Yamakoshi, S. Tsuchiya, J.C. Hu, K. Gomi, T. Arai, J.D. Bartlett, J.P. Simmer (2009) Mmp-20 and Klk4 cleavage site preferences for amelogenin sequences. J Dent Res 88: 823–828.
19.
Nishikawa, S., S. Tsukita, S. Sasa (1990) Localization of adherens junction proteins along the possible sliding interface between secretory ameloblasts of the rat incisor. Cell Struct Funct 15: 245–249.
20.
Obara, N., Y. Suzuki, Y. Nagai, M. Takeda (1998) Expression of E- and P-cadherin during tooth morphogenesis and cytodifferentiation of ameloblasts. Anat Embryol (Berl) 197: 469–475.
21.
Ozdemir, D., P.S. Hart, O.H. Ryu, S.J. Choi, M. Ozdemir-Karatas, E. Firatli, N. Piesco, T.C. Hart (2005) MMP20 active-site mutation in hypomaturation amelogenesis imperfecta. J Dent Res 84: 1031–1035.
22.
Palacios, J., N. Benito, R. Berraquero, A. Pizarro, A. Cano, C. Gamallo (1995) Differential spatiotemporal expression of E- and P-cadherin during mouse tooth development. Int J Dev Biol 39: 663–666.
23.
Papagerakis, P., H.K. Lin, K.Y. Lee, Y. Hu, J.P. Simmer, J.D. Bartlett, J.C. Hu (2008) Premature stop codon in MMP20 causing amelogenesis imperfecta. J Dent Res 87: 56–59.
24.
Sanceau, J., S. Truchet, B. Bauvois (2003) Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing’s sarcoma cells. J Biol Chem 278: 36537–36546.
25.
Sorkin, B.C., M.Y. Wang, J.M. Dobeck, K.L. Albergo, Z. Skobe (2000) The cadherin-catenin complex is expressed alternately with the adenomatous polyposis coli protein during rat incisor amelogenesis. J Histochem Cytochem 48: 397–406.
26.
Terling, C., R. Heymann, B. Rozell, B. Obrink, J. Wroblewski (1998) Dynamic expression of E-cadherin in ameloblasts and cementoblasts in mice. Eur J Oral Sci 106(suppl 1): 137–142.
27.
Thoreson, M.A., P.Z. Anastasiadis, J.M. Daniel, R.C. Ireton, M.J. Wheelock, K.R. Johnson, D.K. Hummingbird, A.B. Reynolds (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol 148: 189–202.
28.
Xiao, K., D.F. Allison, K.M. Buckley, M.D. Kottke, P.A. Vincent, V. Faundez, A.P. Kowalczyk (2003) Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells. J Cell Biol 163: 535–545.
29.
Zalzal, S.F., C.E. Smith, A. Nanci (2008) Ameloblastin and amelogenin share a common secretory pathway and are co-secreted during enamel formation. Matrix Biol 27: 352–359.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.